Inhaled corticosteroids in asthmatic children: Are they as safe in infants and preschoolers as in older children? A review

Current Drug Safety

Volumn 3, Issue 1, 2008, Pages 35-45

  Garcia Marcos, Luis ^a,c   Ros Lucas, Jose A ^b   Sanchez Solis, Manuel ^a  

^a Arrixaca University Children's Hospital   (Spain)

^b Hospital Los Arcos   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

Adverse effects; Asthma; Inhaled corticosteroids; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE;

ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BODY HEIGHT; BONE MINERALIZATION; CATARACT; CHICKENPOX; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; CONVULSION; COUGHING; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DYSPHONIA; FIRST PASS EFFECT; FOLLOW UP; GROWTH DISORDER; GROWTH RATE; HOARSENESS; HUMAN; HYPERTROPHY; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFANT; LOW DRUG DOSE; METERED DOSE INHALER; NEBULIZER; PEDIATRICS; PERIORAL DERMATITIS; PHARMACODYNAMICS; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PURPURA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN BRUISING; SKIN DISEASE; THRUSH; TONGUE DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; AGING; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT;

EID: 38949163241     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488608783334005     Document Type: Review

References (122)

1. Pocket guide for asthma management and prevention in children. GINA, 2006.
2. British guideline on the management of asthma. A national clinical guideline. Revised edition November 2005. Edinburgh: 2005.
3. Busquets Monge RM, Escribano Montaner A, Fernández Benitez M, et al. Consensus statement on the management of paediatric asthma. Allergol Immunopathol (Madr) 2006; 34: 88-101.
4. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol 1998; 25: 1-17.
5. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354: 1985-1997.
6. O'Riordan TG. Optimizing delivery of inhaled corticosteroids: matching drugs with devices. J Aerosol Med 2002; 15: 245-250.
7. Cotes PM, McLean A, Sayer JB. Absortion of inhaled hydrocortisone. Lancet 1954; ii: 807-808.
8. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972; 1: 585-590.
9. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
10. Wyatt R, Waschek J, Weinberger M, Sherman B. Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. N Engl J Med 1978; 299: 1387-1392.
11. Reilly SM, Hambleton G, Adams JE, Mughal MZ. Bone density in asthmatic children treated with inhaled corticosteroids. Arch Dis Child 2001; 84: 183-184.
12. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-441.
13. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990; 141: S59-S69.
14. Burke C, Power CK, Norris A, Condez A, Schmekel B, Poulter LW. Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur Respir J 1992; 5: 73-79.
15. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006; 130: 1301-1311.
16. Szefler SJ. Glucocorticoid therapy for asthma: clinical pharmacology. J Allergy Clin Immunol 1991; 88: 147-165.
17. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44: 37-47.
18. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
19. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23: 11-33.
20. Valotis A, Hogger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 2004; 5: 7.
21. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91(Suppl A): 22-28.
22. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005; 12: 201-209.
23. Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 2006; 29: 599-612.
24. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate. Clin Ther 2006; 28: 319-331.
25. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45: 146-152.
26. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213-219.
27. Dubus JC, Marguet C, Deschildre A, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 2001; 56: 944-948.
28. Toogood JH, Jennings B, Baskerville J, Anderson J, Johansson SA. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis 1984; 65: 35-44.
29. Williams AJ, Baghat MS, Stableforth DE, Cayton RM, Shenoi PM, Skinner C. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983; 38: 813-821.
30. Shaw NJ, Edmunds AT. Inhaled beclomethasone and oral candidiasis. Arch Dis Child 1986; 61: 788-790.
31. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006; 130: 41S-53S.
32. Powell H, Gibson PG. Inhaled corticoseroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225.
33. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev 2004; CD002310.
34. Dubus JC, Mely L, Huiart L, Marguet C, Le Roux P. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundam Clin Pharmacol 2003; 17: 627-631.
35. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103: 414-421.
36. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006; 148: 377-383.
37. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83: 231-239.
38. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006; 41: 954-961.
39. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowin K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immumol 1998; 102: 789-796.
40. Autio P, Karjalainen J, Risteli L, Risteli J, Kiistala U, Oikarinen A. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med 1996; 153: 1172-1175.
41. Linder N, Kuint J, German B, Lubin D, Loewenthal R. Hypertrophy of the tongue associated with inhaled corticosteroid therapy in premature infants. J Pediatr 1995, 127: 651-653.
42. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997; 52: 686-689.
43. Pescollderungg L, Radetii G, Gottardi E, Peroni DG, Pietrobelli A, Boner AL. Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test. Thorax 2003; 58: 227-230.
44. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993; 329: 1703-1708.
45. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 1990; 45: 736-739.
46. Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993; 48: 967-973.
47. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: 891-894.
48. Lipworth BJ. Adrenal suppression with inhaled corticosteroids. Ann Allergy Asthma Immunol 2001; 87: 359-361.
49. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
50. Kannisto S, Korppi M, Reines K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000; 85: 652-657.
51. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-1076.
52. Priftis KN, Papadimitriou A, Gatsopoulou E, Yiallouros PK, Fretzayas A, Nicolaidou P. The effect of inhaled budesonide on adrenal and growth suppression in asthmatic children. Eur Respir J 2006; 27: 316-320.
53. Goldberg S, Algur N, Levi M, et al. Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Ann Allergy Asthma Immunol 1996; 76: 234-238.
54. Shenoy SD, Swift PG, Cody D. Growth impairment and adrenal suppression on low-dose inhaled beclomethasone. J Paediatr Child Health 2006; 42: 143-144.
55. Crowley S. Inhaled glucocorticoids and adrenal function: an update. Paediatr Respir Rev 2003; 4: 153-161.
56. Drake AJ, Howells RJ, Shield JP, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002; 324: 1081-1082.
57. Lipworth BJ. Adrenal insufficiency after treatment with fluticasone. Second line controller treatment might have been tried. BMJ 2002; 325: 836.
58. Mohn A, Verini M, Mele R, De Leonardis C, Chiarelli F. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J 2004; 23: 354-355.
59. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2001; 85: 330-334.
60. Paton J, Jardine E, McNeill E, et al. Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child 2006; 91: 808-813.
61. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461.
62. Todd GR, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 2002; 19: 1207-1209.
63. de Vries TW, Langen-Wouterse JJ, van Puijenbroek E, et al. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol 2006; 62: 343-346.
64. Asthma in adults and schoolchildren. The General Practioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. Thorax 1997; 52(Suppl 1): S2-5, S20.
65. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006; 41: 954-961.
66. Russell G. Asthma and growth. Arch Dis Child 1993; 69: 695-698.
67. Norjavaara E, Gerhardsson DV, Lindmark B. Reduced height in swedish men with asthma at the age of conscription for military service. J Pediatr 2000; 137: 25-29.
68. Raza J, Massoud AF, Hindmarsh PC, Robinson IC, Brook CG. Direct effects of corticotrophin-releasing hormone on stimulated growth hormone secretion. Clin Endocrinol (Oxf) 1998; 48: 217-222.
69. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996; 25: 699-717.
70. Kamada AK, Szefler SJ. Glucocorticoids and growth in asthmatic children. Pediatr Allergy Immunol 1995; 6: 145-154.
71. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 2001; 164: 521-535.
72. Price J, Hindmarsh P, Hughes S, Effthimiou J. Evaluating the effects of asthma therapy on childhood growth: principles of study design. Eur Respir J 2002; 19: 1167-1178.
73. Jonasson G, Carlsen KH, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55: 740-748.
74. Doull IJ, Campbell MJ, Holgate ST. Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1998; 78: 172-173.
75. Carlsen KH, Gerritsen J. Inhaled steroids in children: adrenal suppression and growth impairment. Eur Respir J 2002; 19: 985-988.
76. Saha MT, Laippala P, Lenko HI. Clinical observations on catch-up growth in asthmatic children following withdrawal of inhaled gluccorticosteroids. Pediatr Pulmonol 1998; 26: 292-294.
77. Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr 1999; 134: 422-427.
78. Rao R, Gregson RK, Jones AC, Miles EA, Campbell MJ, Warner JO. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J 1999; 13: 87-94.
79. Ferguson AC, Van Bever HP, Teper AM, Lasytsya O, Goldfrad CH, Whitehead PJ. A comparison of the relative growth velocities with budesonide and fluticasone propionate in children with asthma. Respir Med 2007; 101: 118-129.
80. Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997; 99: 466-474.
81. Van Bever HP, Desager KN, Lijssens N, Weyler JJ, Du Caju MV. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol 1999; 27: 369-375.
82. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064-1069.
83. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; CD003537.
84. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004; 114: 469-473.
85. Bahceciler NN, Sezgin G, Nursoy MA, Barlan IB, Basaran MM. Inhaled corticosteroids and bone density of children with asthma. J Asthma 2002; 39: 151-157.
86. Martinati LC, Bertoldo F, Gasperi E,.Fortunati P, Lo CV, Boner AL. Longitudinal evaluation of bone mass in asthmatic children treated with inhaled beolomethasone dipropionate or cromolyn sodium. Allergy 1998; 53: 705-768.
87. Reilly SM, Hambleton G, Adams JE, Mughal MZ. Bone density in asthmatic children treated with inhaled corticosteroids. Arch Dis Child 2001; 84: 183-184.
88. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990; 300: 1548-1151.
89. Agertoft L, Larson FE; Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998; 12: 130-135.
90. Choong K, Zwaigenbaum L, Onyett H. Severe varicella after low dose inhaled corticosteroids. Pediatr Infect Dis J 1995; 14: 809-811.
91. Murphy K, Ververeli K, Harvey BM, et al. Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non-steroidal conventional asthma therapy. Int J Clin Pract 2006; 60: 1548-1557.
92. Nursoy MA, Bakir M, Barlan IB, Basaran MM. The course of chickenpox in asthmatic children receiving inhaled budesonide. Pediatr Infect Dis J 1997; 16: 74-77.
93. Shaikh WA. Pulmonary tuberculosis in patients treated with inhaled beclomethasone. Allergy 1992; 47: 327-330.
94. Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000; 19: 215-218.
95. Behbehani AH, Owayed AF, Hijazi ZM, Eslah EA, Al Jazzaf AM. Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Pediatr Opthalmol Strabismus 2005; 42: 23-27.
96. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343: 1054-1063.
97. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthahnol 2003; 87: 1247-1251.
98. Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol 1991; 88: 384-389.
99. Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. Budesonide Inhalation Suspension Study Group. J Allergy Clin Immunol 1999; 104: 191-199.
100. Fok TF, Monkman S, Dolovich M, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21: 301-309.
101. Zainudin BM, Biddiscombe M, Tolfree SE, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45: 469-473.
102. Turpeinen M, Nikander K, Malmberg LP, Pelkonen A. Metered dose inhaler add-on devices: is the inhaled mass of drug dependent on the size of the infant? J Aerosol Med 1999; 12: 171-176.
103. Lodrup Carlsen KC, Nikander K, Carlsen KH. How much nebulised budesonide reaches infants and toddlers? Arch Dis Child 1992; 67: 1077-1079.
104. Dubus JC, Anhoj J. Inhaled steroid delivery from small-volume holding chambers depends on age, holding chamber, and interface in children. J Aerosol Med 2004; 17: 225-230.
105. Janssens HM, de Jongste JC, Hop WC, Tiddens HA. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest 2003; 123: 2083-2088.
106. Reid A, Murphy C, Steen HJ, McGovern V, Shields MD. Linear growth of very young asthmatic children treated with high-dose nebulized budesonide. Acta Paediatr 1996; 85: 421-424.
107. Scott MB, Ellis MH, Cruz-Rivera M, Fitzpatrick S, Smith JA. Once-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma. Ann Alergy Asthma Immunol 2001; 87: 488-495.
108. Mendelson L, Cook D, Cruz-Rivera M, Fitzpatrick S, Smith JA. Twice-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma. J Asthma 2002; 39: 227-237.
109. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999; 104: 200-209.
110. Skoner DP, Szefler SJ, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol 2000; 105: 259-268.
111. Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc 2001; 22:359-366.
112. Irani AM, Cruz-Rivera M, Fitzpatrick S, Hoag J, Smith JA. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol 2002; 88:306-312.
113. White MV, Cruz-Rivera M, Walton-Bowen K. The efficacy and safety of budesonide inhalation suspension: a nebulizable corticosteroid for persistent asthma in infants and young children. Fam Med 1999; 31: 337-345.
114. Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999; 340: 1005-1010.
115. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999; 160: 126-131.
116. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113: e87-e94.
117. Carlsen KC, Stick S, Kamin W, Cirule I, Hughes S, Wixon C. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Respir Med 2005; 99: 1393-1402.
118. Qaqundah PY, Sugerman RW, Ceruti E, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr 2006; 149: 663-670.
119. Teper AM, Colom AJ, Kofman CD, Maffey AF, Vidaurreta SM, Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 2004; 37: 111-115.
120. Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months, with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005; 146: 91-95.
121. Delacourt C, Dutau G, Lefrancois G, Clerson P. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir Med 2003; 97(Suppl B): S27-S33.
122. Anhoj J, Bisgaard AM, Bisgaard H. Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics 2002; 109: E40.